---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-26-000025"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:48:02.472902+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences reports Q1 2026 sales $811M (up 44%); agrees to acquire Soleno Therapeutics for $2.9B

## Summary
- Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).
- Definitive agreement to acquire Soleno Therapeutics for $53.00 per share ($2.9B equity value), expected to close in Q2 2026.
- Initiated Phase 2 study of NBI-1117570 (dual M1/M4 agonist) for schizophrenia and Phase 1 study of NBIP-’2118 (CRF2 agonist) for obesity.
- Reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7-$2.8 billion and total cash of $2.65 billion at March 31, 2026.

## SEC filing metadata
- accession: 0000914475-26-000025
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/0000914475-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/nbix-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-26-000025
- JSON: https://secwatch.observer/filing/0000914475-26-000025.json
- Plain text: https://secwatch.observer/filing/0000914475-26-000025.txt

## Key facts
- Earnings Releases
  NEUROCRINE BIOSCIENCES INC reported first quarter ended March 31, 2026 results: revenue 814.5 million dollars, net income 197.9 million dollars, EPS 1.91 dollars per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Revenue: 814.5 million dollars
  - Net income: 197.9 million dollars
  - EPS: 1.91 dollars per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Neurocrine Biosciences Reports First-Quarter 2026 Financial Results Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO , May 5, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/0000914475-26-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.